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Abstract
Background: Perioperative allogenic transfusion is required in almost 50% of patients undergoing cardiac surgery
and is associated with higher risk of mortality and morbidity (Xue et al., Lancet 387:1905, 2016; Ferraris et al., Ann
Thorac Surg 91:944–82, 2011). Acute normovolemic hemodilution (ANH) is recommended as a potential strategy
during cardiac surgery, but the blood conservation effect and the degree of ANH was still controversial. There is
also an increasing concern about the improved outcomes associated with ANH. Therefore, a better understanding
of the effect of mild volume ANH during cardiac surgery is urgently needed.
Methods: This retrospective study included 2058 patients who underwent cardiac surgery between 2010 and 2015.
The study population was split into two groups (with and without mild volume ANH). Propensity score adjustment
analysis was applied. We reported the association between the use of mild volume ANH and perioperative
outcomes.
Results: A total of 1289 patients were identified. ANH was performed in 358 patients, and the remaining 931
patients did not receive any ANH. Five hundred of the total patients (38.8%) received perioperative RBC
transfusions, 10% (129/1289) of patients received platelet, and 56.4% (727/1289) of patients received fresh frozen
plasma transfusions. Mild volume ANH administration was significantly associated with decreased intraoperative
RBC transfuse rate (8.5% vs. 14.4%; p = 0.013), number of RBC units (p = 0.019), and decreased postoperative
pulmonary infection (6.8 vs. 11.3%; p = 0.036) during cardiac surgery. However, there was no significant difference
regarding intraoperative fresh frozen plasma (FFP) and platelet concentrate transfusions, as well as postoperative
and total perioperative allogeneic transfusions. Furthermore, there was no significant difference regarding
postoperative outcomes including mortality, prolonged wound healing, stroke, atrial fibrillation, reoperation for
postoperative bleeding and acute kidney injury. There was also no difference in postoperative ventilation time,
length of ICU and hospital stay.
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Conclusion: Based on the 5-year experience of mild volume ANH in cardiac surgeries with CPB in our large
retrospective cohort, mild volume ANH was associated with decreased intraoperative RBC transfusion and
postoperative pulmonary infection in Chinese patients undergoing cardiac surgery. However, there was no
significant difference regarding postoperative and total perioperative allogeneic transfusions.
Keywords: Hemodilution, Transfusion, Complication, Cardiac surgery
Background
In China, blood shortage is now becoming an important
public health concern, and the lack of adequate blood
donation is considered to be the main cause [1]. Peri-
operative allogenic transfusion is required in about 50%
of patients undergoing cardiac surgery [2], but it is asso-
ciated with higher risk of mortality and morbidity (infec-
tion, lung injury, renal failure, and stroke) [3–5]. Hence,
many blood conservation techniques are recommended
of which acute normovolemic hemodilution (ANH) may
be considered as an adjuvant in appropriate patients [2].
Thus far, no consensus has been achieved in the re-
sults of published studies on ANH. Many trials have
confirmed the positive effects of ANH in reducing peri-
operative allogeneic transfusions [6, 7]; however, other
studies have reported negative effects [8, 9]. Another im-
portant debated point is the degree of ANH performed.
Some authors consider that only a large volume of ANH
is useful or effective in minimizing the need for allogen-
eic transfusions [7, 10]; however, Kahraman et al. ob-
served no differences between the effect of mild and
high volume of ANH on postoperative bleeding and
perioperative blood transfusions [11]. Furthermore, there
may be a risk of performing moderate or severe ANH in
patients with a lower preoperative hematocrit level in
cardiac surgery with cardiopulmonary bypass (CPB)
which would lead to hemodilution [12].
There is also an increasing concern about the im-
proved outcomes associated with ANH [7, 13, 14]; the
safety of ANH still remains uncertain [15]. We per-
formed this study to assess the relationship between
mild volume ANH, perioperative transfusions, and out-
comes in Chinese patients undergoing cardiac surgery.
Methods
Study population and design
The present study was a single center, retrospective
study which was approved by the Ethics Committee of
Zhejiang University (Hangzhou, China; No.2016-021),
with patient consent waived. A total of 2058 consecutive
adult patients underwent cardiac surgeries with CPB
from January 1, 2010, to December 31, 2015 and ANH
was performed throughout all 5 years. The following ex-
clusion criteria were applied as they were unsuitable for
ANH: (1) low weight (weight <50 kg for men and <45 kg
for women); (2) ASA (American Standards Association)
class V; (3) emergent or redo surgery; (4) previous shock
or left ventricular ejection fraction (LVEF) <35%; (5) pre-
vious coexistent disease (endocarditis; a history of myo-
cardial infarction in the previous 30 days; chronic
obstructive pulmonary disease [COPD]; anemia; chronic
kidney disease [CKD]; serum albumin level [ALB] <25 g/
L); (6) international normalized ratio (INR) >1.5 or
platelet count <100 × 103/mm3; (7) acquired or inherited
bleeding disorders; (8) cancer disease. Then the study
population was devided into ANH group (with ANH)
and non-ANH group (without ANH).
Perioperative medical record information including
demographic characteristics, patient history (preoperative
medications, coexistent disease and other risk factors), op-
erative data, perioperative allogeneic transfusions, and
postoperative complication were retrieved from the hos-
pital medical records during the entire hospitalization
period regardless of days. An independent investigator
reviewed all data.
ANH techniques and transfusion strategy
General anesthesia and standard monitoring were per-
formed. According to institutional standards, body
temperature of patients was maintained at 30 °C during
CPB. When the surgery was finished, patients were
rewarmed to 37 °C and weaned from CPB. ANH was
performed after induction of anesthesia and before
heparinization for CPB [7]. The mild volume ANH [8]
was performed with 5–8 ml/kg of whole blood withdrawn
from an introducer of Fast-Cath catheter (St. Jude Med-
ical, USA) into standard citrate phosphate-dextrose collec-
tion bags by gravity. The removed blood volume was
simultaneously replaced with an equal volume of hydro-
xyethyl starch solutions (6%Haes 130/0.4; Fresenius Kabi,
Stans, Switzerland). Collected blood was kept at 4 °C
temperature refrigerator without shaker.
Transfusion criteria were the same in both groups.
The cell saver was routinely performed, the adminis-
tration of antifibrinolytics was apllied according to the
anesthetist’s judgment, and additional blood transfu-
sions were deliberately determined by the surgery
team caring of the patients. Blood transfusions were
usually carried out when the following criteria were
met [2] and other additional decisions were made
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according to the patient’s clinical condition. Red blood
cells (RBC) were transfused when hemoglobin concen-
trations was <6 g/dL during CPB and <7 g/dL after
CPB. When international normalized ratio (INR) >1.4
or activated partial prothrombin time (aPTT) >50 s or
R time >10 min in Thromboelastometry test (TEG),
prothrombin complex concentrate (PCC) was admin-
istered (20–30 IU/kg). If the above mentioned parame-
ters prolongation did not respond to administration of
PCC or there occured hypovolemia, Fresh frozen
plasma (FFP) was transfused (10–15 mL/kg). Platelets
were transfused when platelets count <50 × 109/L and
fibrinogen concentrate (Fb) was administered of 25–
50 mg/kg when Fb <1.5 g/L. Activated recombinant
factor VII (rVIIa) was considered of 90 ug/kg as rescue
therapy if the bleeding still existed while INR <1.4,
aPTT <50 s, Fb >2 g/L, platelet count >100 × 109/L.
When transfusion criteria were met during the sur-
gery, the withdrawn blood was reinfused firstly. If
transfusion criteria were not met till the end of sur-
gery, the withdrawn blood was also reinfused before
the patients were transferred out of the operation
room. The reinfusion of withdrawn blood was per-
formed within 6 h. Blood recovered from the extracor-
poreal circuit system (pumped blood) was not
accounted into the volume of the blood transfusions.
Perioperative endpoints
The end points occurred during the hospitalization were
recorded in patient medical documents. The primary
endpoint was any perioperative transfusions. Other end-
points included in-hospital mortality (intraoperation and
postoperation death, which were defined as death in the
operation room and death after operation up to dis-
charge seperately), morbidity, duration of mechanical
ventilation, length of ICU (intensive care unit) stay,
length of hospital stay (LOS) and hemostatic drugs
adminstration. Hospital morbidities included the follow-
ing: (1) pulmonary infection was confirmed based on
symptoms (fever and expectoration) and laboratory evi-
dence (culture-positive sputum, chest roentgenogram, or
computed tomography findings) by a physician review-
ing the medical data [16]; (2) prolonged wound healing
which was defined as >7 days for wound healing; (3)
stroke which was a new ischemic cerebrovascular acci-
dent confirmed by radiological evidence with a neuro-
logical deficit lasting for more than 24 h and with
radiological evidence [17]; (4) new-onset atrial fibrilla-
tion (AF) [18]; (5) re-exploration for bleeding during
hospitalization; (6) acute kidney injury (AKI), defined by
Improving Global Outcomes criteria [19]: increase in
serum creatinine (Cr) by ≥26.5 μmol/l within 48 h; or In-
crease in Cr to ≥1.5 times baseline within the previous
7 days. AKI is staged for severity according to the
following criteria: stage 1 (Cr ≥26.5 μmol/L above base-
line or 1.5–1.9 times baseline), stage 2 (Cr 2.0–2.9 times
baseline), or stage 3 (Cr ≥3 times baseline or postopera-
tive Cr of ≥353.6 μmol/L, or initiation of renal replace-
ment therapy).
Statistical methods
Descriptive analyses of variables were used to summarize
data. The normal distributed variables were expressed as
mean ± standard deviation (SD) and compared with student
t-test. Abnormal continuous variables were expressed as
median (interquartile range (IQR)) and evaluated with
Mann-Whitney U-test.respectively. Chi-square or Fisher’s
exact test was used to compare proportions between the
two groups. Missing continuous variables of baseline pa-
rameters were less than 10% and were replaced by median
in Table 1. All reported p values were two sided, and values
of p < 0.05 were considered to be statistically significant.
Statistical analysis was performed with SPSS version 18.
To minimize the effect of selection bias on outcomes, we
used propensity score matching for clinical characteristics
to reduce distortion by confounding factors. Using propen-
sity score analysis by the method of nearest-neighbor
matching, we generated a set of matched cases (ANH) and
controls (non-ANH). According to the propensity score
matching, 354 pairs of patients were identified for postoper-
ative analysis. A propensity score was generated for each
patient from a multivariable logistic regression model on
the basis of the covariates using clinical characteristics data
(Table 1) from the institutional registry as independent vari-
ables, with treatment type (ANH vs. Non-ANH) as a binary
dependent variable. We matched patients using a greedy-
matching algorithm with a caliper width of 0.1 of the esti-
mated propensity score. A matching ratio of 1:1 was used.
We evaluated post match covariate balance by comparing
the balance of baseline covariates between patients with
ANH and non-ANH before and after matching using abso-
lute standardized differences [20].
Results
Baseline parameters
A total of 1289 patients were identified and divided into
two groups: patients who received ANH (ANH group, n =
358, 27.8%) and those who did not receive ANH (non-
ANH group, n = 931, 72.2%) during the operative period
(Fig. 1). The mean removed blood was 346 mL in the ANH
group. The average age of the study population was
51 years, 52.1% were females, 71.8% with ASA class III,
5.7% with ASA class IV, and 24.5% had NYHA class III and
IV. A total of 38.7% of the total patients underwent com-
plex cardiac (combined coronary artery bypass graft surgery
and valve surgery or multi-valve surgery) or aortic surgery
(Aortic dissections, type A and B, thoracic aortic aneurysms
or Aortic valve surgery with ascending aortic replacement).
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The clinical characteristics of the two matched groups (with
and without ANH) extracted by propensity analysis were
presented in Table 1. According to the standardized differ-
ence, covariate balance between the matched pairs was
confirmed. An additional data material file shows in detail
(see Additional file 1).
Operative characteristics
As ANH technique was performed, the blood hematocrit
was lower in the ANH group (p < 0.05). The ANH group
had more intraoperative cristalloids and colloids volume
(2272 ± 610 vs. 2140 ± 770) mL; p = 0.011), but there was
no significant difference in blood loss, urine output, and
pump blood between the two groups. No significant dif-
ference was observed between the two matched groups
regarding operative characteristics including surgery
type, the number of intra-aortic balloon pump (IABA)
utilized, cardiopulmonary bypass time, anesthesia time,
surgery time, calcium content, and the blood pH
(Table 2).
Perioperative allogeneic transfusions
Of the total 1289 patients, 500 patients (38.8%) received
perioperative RBC transfusions, 10% (129/1289) of
Table 1 Demographic and Clinical characteristics of the two study groups before and after propensity score matching
Entire sample Propensity-matched group
Preoperative characteristics ANH p-value ANH p-value
Yes (n = 358) No (n = 931) Yes (n = 354) No (n = 354)
Age [median (SD); yr] 50 ± 12 51 ± 13 0.139 50 ± 12 50 ± 13 0.866
Male/female, no.(%) 224/134 (62.6%) 394/537 (42.3%) <0.001 220/134 (62.1%) 222/132 (62.7%) 0.877
Height [median (SD); cm] 164 ± 7 162 ± 7 <0.001 164 ± 7 164 ± 7 0.761
Weight [mean (SD); kg] 63 ± 10 60 ± 10 <0.001 63 ± 10 62 ± 10 0.580
Estimated blood volume [mean (SD); mL] 4298 ± 779 4045 ± 722 <0.001 4285 ± 765 4258 ± 750 0.636
ASA, no. (%) 0.070 0.230
I 1 (0.3%) 4 (0.4) 1 (0.3%) 3 (0.8%)
II 79 (22.1%) 206 (22.1%) 79 (22.3%) 77 (21.8%)
III 248 (69.3%) 678 (72.8%) 244 (68.9%) 256 (72.3%)
IV 30 (8.4%) 43 (46%) 30 (8.5%) 18 (5.1%)
NYHA class III/IV, no.(%) 83 (23.2%) 233 (25%) 0.491 81 (22.9%) 75 (21.2%) 0.586
History of smoking, no. (%) 108 (30.2%) 204 (21.9%) 0.002 108 (30.5%) 100 (28.2%) 0.509
Coexistent disease
AF, no. (%) 81 (22.6%) 222 (23.8%) 0.644 80 (22.6%) 82 (23.2%) 0.858
Hypertension, no. (%) 75 (20.9%) 209 (22.4%) 0.561 74 (20.9%) 79 (22.3%) 0.648
Diabetes, no. (%) 17 (4.7%) 63 (6.8%) 0.179 17 (4.8%) 18 (5.1%) 0.862
HLP, no. (%) 5 (1.4%) 6 (0.6%) 0.191 5 (1.4%) 2 (0.6%) 0.451
Cerebrovascular disease, no. (%) 16 (4.5) 37 (4.0) 0.688 16 (4.5) 16 (4.5) 1.000
Preoperative Medication
ACEI and ARB, no. (%) 28 (7.8%) 77 (8.3%) 0.792 28 (7.9%) 29 (8.2%) 0.890
β-blockers, no. (%) 19 (5.3%) 66 (7.1%) 0.248 19 (5.4%) 22 (6.2%) 0.629
Calcium Channel Blockers, no. (%) 25 (7.0%) 71 (7.6%) 0.694 24 (6.8%) 19 (5.4%) 0.431
Diuretics, no. (%) 16 (4.5%) 70 (7.5%) 0.049 16 (4.5%) 13 (3.7%) 0.569
Preoperative laboratory examination
T-ch [median (SD); mmol/L] 4.5 ± 1.0 4.4 ± 1.1 0.178 4.5 ± 1.0 4.4 ± 1.1 0.305
Cr [median (SD); umol/L] 70 ± 15 67 ± 16 <0.001 70 ± 15 70 ± 17 0.976
ALB [median (SD); g/L] 42 ± 4 42 ± 4 0.182 42 ± 4 42 ± 4 0.535
HCT [median (SD); %] 42 ± 5 40 ± 4 <0.001 42 ± 4 42 ± 4 0.918
Propensity score [median (SD)] 0.33 ± 0.12 0.26 ± 0.11 <0.001 0.32 ± 0.12 0.32 ± 0.11 0.840
#: Fisher’s exact test was used; BMI body mass index, ASA American Society of Anesthesiologists, NYHA New York Heart Association, AF atrial fibrillation, HLP
hyperlipidaemia, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, MI myocardial infarction in 30 days before operation, ARB angiotensin
receptor blockers, ACEI angiotensin converting enzyme inhibitors, LVEF left ventricular ejection fraction, T-ch serum cholesterol, Cr serum creatinine, ALB albumin,
HCT hematocrit
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patients received platelet, 56.4% (727/1289) of patients
received FFP transfusions. Compared to the non-ANH
group, the intraoperative RBC transfusions rate (8.5% vs.
14.4%; p = 0.013) and number of RBC units (p = 0.019)
decreased significantly in the ANH group. However,
there was no significant difference regarding intraopera-
tive hemostatic drugs, FFP and platelet concentrate
transfusions, as well as postoperative and total peri-
operative allogeneic transfusions (Table 3).
Postoperative outcomes after propensity matching
Eighteen of the total 1289 patients (1.4%) died during
hospitalization, of which died in the operating room
were four. Patients who died in the operating room
after propensity matching were excluded from the post-
operative outcomes analysis (n = 2). Patients who had
preexisting renal dysfunction (serum creatinine level
>124 μmol/L for women and >141 μmol/L for men or
requiring renal replacement therapy) were excluded
from the AKI analysis (n = 52) and patients with a pre-
existing history of AF were excluded from the AF ana-
lysis after propensity score matching (n = 161).
None of the patients experienced pulmonary embol-
ism. Approximately 8.9% (115/1289) of patients devel-
oped postoperative pulmonary infection during
hospitalization. The rate of pulmonary infection (6.8
vs. 11.3%; p = 0.036) was significantly declined in the
ANH group as compared to that in the non-ANH
group. No differences were found in the incidence of
mortality, prolonged wound healing, stroke, AF, reop-
eration for postoperative bleeding and AKI between
the two groups. There was also no difference in post-
operative ventilation time, length of ICU and hospital
stay (Table 4).
Discussion
In our retrospective analysis of patients undergoing car-
diac surgery with CPB, we found that mild volume ANH
was associated with decreased intraoperative RBC trans-
fusions rate and number of RBC units after data adjust-
ment for preoperative risk factors. However, there was
no significant difference regarding postoperative and
total perioperative allogeneic transfusions. Our results
further supported previous findings that the use of ANH
could reduce intraoperative RBC transfusions in patients
undergoing cardiac surgery [6, 7, 21], even though blood
loss was similar between the ANH and non-ANH groups
in our study. Some meta-analysis also supported that
ANH is effective in minimizing blood transfusion in pa-
tients undergoing cardiac surgery [15, 22].
However, the utility of mild volume ANH in reducing
allogeneic blood transfusions in cardiac surgery is still
controversial. Several studies have proved that mild vol-
ume ANH was not effective in reducing the number of
allogeneic erythrocytes units [8, 23], but others have
proven otherwise [6]. Our results support the positive
finding that mild volume ANH could reduce intraopera-
tive blood transfusions. The variations in blood saving
strategy and surgery type may be the major reasons for
our finding being different from other studies. Although
Valter Casati et al.’s study did not find positive efficacy
of low-volume ANH [8], we noticed that there was a de-
creasing trend of intraoperative RBC transfusions in the
ANH group compared to non-ANH group (4.9% vs. 7%).
Another potential reason was that their case mix was
easier (over 50% were single valve surgeries), which leads
to less blood loss and transfusions. However, more than
38.7% of the surgeries in our cohort were complex car-
diac and aortic surgeries, resulting in that more patients
required intraoperative RBC transfusions in both the
Fig. 1 Study population recruitment summary. LVEF = left ventricular ejection fraction; COPD = chronic obstructive pulmonary disease; CKD =
chronic kidney disease; INR = international normalized ratio; Plt = platelet count; ANH = acute normovolemic hemodilution
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ANH and non-ANH groups (8.5 and 14.4%). Another
point to be noted is that the cell saver technique was
routinely applied in our study as a previous study re-
ported that combination of cell saver with ANH pro-
duced better blood saving effect than ANH alone [24].
Another previous study of Alireza Mahoori et al. on ex-
clusively elective coronary artery bypass graft (CABG)
surgery patients [6] found that mild volume ANH could
decrease requirements of total perioperative RBC trans-
fusions. We failed to observe the similar positive effect
of mild volume ANH on total perioperative RBC trans-
fusions, this variation may mainly due to the different
volumes of blood removed (342 vs. 490 mL) and transfu-
sion triggered criteria between our study and Alireza
Mahoori’s study (hemoglobin concentration <6–7 g/dL
vs. <10 g/dL). The less strict transfusion triggered cri-
teria in Alireza Mahoori’s study may lead to more trans-
fusions rate compared to our cohort (57% vs. 27%).
Although ANH has been proved to reduce postoperative
allogenic blood transfusions during cardiac surgery [7],
our study failed to show these positive findings. A com-
prehensive blood saving strategy including antifibrinolytic
agent [25] and TEG [26] has been applied and was dem-
onstrated to reduce transfusion requirements. Thus the
evidence of ANH may be less effective. The mild volume
of ANH may also contribute to the less beneficial blood
conservation effect, as Joshua Goldberg found that the re-
duction in allogeneic transfusions is more significant with
greater volume ANH (≥800 mL) in cardiac surgery [7].
There is not much evidence regarding clinical outcome
benefits of mild ANH in patients undergoing cardiac sur-
gery. A recent article found that ANH was related to im-
proved outcomes including renal failure, 30-day mortality,
and length of hospital stay [7], and moderate ANH pro-
vided further cardioprotective effects during cardiac surgery
[13, 14]. However, some other authors mentioned that
greater hemodilution might be associated with adverse
complications, especially in patients with preexisting coron-
ary disease [27]. In another study of patients undergoing







ANH [mean (SD); mL] 342 ± 138
Operative Characteristics
Intra-aortic balloon pump, no. (%) 1 (0.3%) 1 (0.3%) 1.000
Duration of anesthesia
[mean (SD); min]
297 ± 98 305 ± 110 0.325
Duration of surgery
[mean (SD); min]
252 ± 89 260 ± 110 0.244
CPB time [mean (SD); min] 125 ± 59 129 ± 63 0.399
Type of surgery, no. (%) 0.168
CABG 23 (6.5%) 30 (8.5%)
Valve surgery 137 (38.7%) 121 (34.2%)
Complex cardiac surgery 116 (32.8%) 126 (35.6%)
Aortic surgery 24 (6.8%) 13 (3.7%)
Others surgery 54 (15.3%) 64 (18.1%)
Input and Output
Blood loss [mean (SD); mL] 684 ± 355 678 ± 514 0.855
Urine output [mean (SD); mL] 788 ± 465 730 ± 419 0.084
Pump blood [mean (SD); mL] 512 ± 129 508 ± 139 0.708
Cell salvage [median (SD); mL] 375 ± 267 369 ± 343 0.797
Intraoperative cristalloids and
colloids [mean (SD); mL]
2272 ± 610 2140 ± 770 0.011
Hemostatic drugs Characteristics
Tranexamic Acid, no. (%) 121 (34.2%) 113 (31.9%) 0.523
Prothrombin Complex
Concentrate, no. (%)
6 (1.7%) 7 (20%) 0.780
Fibrinogen concentrate,
no. (%)
6 (1.7%) 10 (2.8%) 0.312
Recombinant activated
factor VII, no. (%)
1 (0.3%) 3 (0.8%) 0.624
Arterial blood gas analysis
Calcium content Pre-CPB
[mean (SD); mmol/L]
1.08 ± 0.10 1.08 ± 0.09 0.871
Blood pH Pre-CPB [mean (SD)] 7.40 ± 0.06 7.39 ± 0.05 0.636
Hct Pre-CPB [mean (SD);%] 38 ± 5 40 ± 5 <0.001
Calcium content End ± CPB
[mean (SD); mmol/L]
0.90 ± 0.13 0.87 ± 0.13 0.086
Blood pH End-CPB [mean (SD)] 7.48 ± 0.08 7.50 ± 0.09 0.055
Hct End-CPB [mean (SD);%] 25 ± 4 27 ± 5 0.003
Table 2 Operative Characteristics (Continued)
Calcium content Post ± CPB
[mean (SD); mmol/L]
1.03 ± 0.17 1.02 ± 0.15 0.628
Blood pH Post-CPB [mean (SD)] 7.37 ± 0.07 7.38 ± 0.08 0.168
Hct Post ± CPB [mean (SD);%] 29 ± 4 30 ± 5 0.021
#: Fisher’s exact test was used; CPB cardiopulmonary bypass, CABG coronary
artery bypass grafting, Valve surgery aortic, mitral and tricuspid valve surgery
without ascending aortic replacement, Complex cardiac surgery combined
coronary artery bypass graft surgery and valve surgery or multi-valve surgery,
Aortic surgery aortic dissections, type A and B, thoracic aortic aneurysms) or
Aortic valve surgery with ascending aortic replacement; Others surgery type
including atrial septal defect, interventricular septal defect, atrial myxoma,
Aneurysm Sinus Valsalva, coronary artery pulmonary artery fistula, patent for-
amen ovale/atrial septal aneurysm surgery, and surgery for cardiac tumors,
Pumped blood blood recovered from the extracorporeal circuit system, CPB car-
diopulmonary bypass, Hb hemoglobin, Hct hematocrit, Pre-CPB before CPB and
after performing ANH, End-CPB at the end of CPB, Post-CPB 30 min after CPB
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pancreaticoduodenectomy, ANH did not seem to decrease
blood transfusions, but lead to more pancreatic anasto-
motic complications for greater intraoperative fluid admin-
istration [28]. Some authors criticize ANH for the possibly
of causing perioperative adverse outcomes including dam-
aged pulmonary function for increased lung fluid volume
[8]. Furthermore, a recent study even found that after
moderate ANH, patients undergoing total hip arthroplasty
showed a hypocoagulable state [29].
Although we did not observe the positive effect of ANH
regarding mortality, stroke, AF, AKI, and resternotomy for
postoperative bleeding, our findings suggest that mild vol-
ume ANH might be associated with lower incidence of
pulmonary infection. Some possible mechanisms may
contribute to this protective effect. First, the indirect effect
of reducing the rate of RBC transfusions may improve
outcomes. RBC transfusions could increase postoperative
pneumonia in patients undergoing CABG surgery [17].
Second, ANH blood was associated with a smaller con-
centration of inflammatory mediators such as interleukin-
10 and neutrophil elastase than predonated autologous
blood [30]. Third, due to the hemodilution-induced blood
viscosity, such protection might be associated with an im-
proved oxygen supply-consumption balance [14]. More
Table 3 Perioperative allogeneic transfusions
Allogeneic transfusions Propensity-matched
ANH Non-ANH p-value
(n = 354) (n = 354)
Intra-operative transfusion
RBC transfusion, no. (%) 30 (8.5%) 51 (14.4%) 0.013
Total RBCs transfusion (U) 164 289 0.019
FFP transfusion, no. (%) 96 (27.1%) 109 (30.8%) 0.281
Total FFP transfusion (ml) 63770 78660 0.225
Platelet transfusion, no. (%) 25 (7.1%) 18 (5.1%) 0.271
Total Platelet transfusion (U) 261 205.7 0.432
Postoperative RBCs transfusion
Postoperative in 24 h, no. (%) 72 (20.4%) 63 (17.8%) 0.389
Postoperative in 24 h
[median (IQR); U]
0 (0 to 0) 0 (0 to 0) 0.407
>24 h after surgical start, no. (%) 24 (6.8%) 25 (7.1%) 0.882
>24 h after surgical start
[median (IQR); U]
0 (0 to 0) 0 (0 to 0) 0.881
Postoperative FFP transfusion
Postoperative in 24 h, no. (%) 90 (25.5%) 93 (26.3%) 0.797
Postoperative in 24 h
[median (IQR); ml]
0 (0 to 230) 0 (0 to 200) 0.914
Postoperative after 24 h, no. (%) 7 (2.0%) 7 (2.0%) 1.000
>24 h after surgical start
[median (IQR); ml]
0 (0 to 0) 0 (0 to 0) 0.996
Postoperative Platelet transfusion
Postoperative in 24 h, no. (%) 10 (2.8%) 9 (2.5%) 0.816
Postoperative in 24 h
[median (IQR); U]
0 (0 to 0) 0 (0 to 0) 0.802
Postoperative after 24 h, no. (%) 1 (0.3%) 2 (0.6%) 0.624#
>24 h after surgical start
[median (IQR); U]
0 (0 to 0) 0 (0 to 0) 0.561
Total Perioperative Allogeneic transfusions
RBC transfusion, no. (%) 98 (27.7%) 96 (27.1%) 0.866
RBCs transfusion (U) 0 (0 to 2) 0 (0 to 2) 0.300
FFP transfusion, no. (%) 153 (43.2%) 157 (44.4%) 0.762
FFP transfusion (ml) 0 (0 to 730) 0 (0 to 630) 0.876
Platelet transfusion, no. (%) 35 (9.9%) 28 (7.9%) 0.355
Platelet transfusion (U) 0 (0 to 0) 0 (0 to 0) 0.380
Postoperative HCT [median (SD); %] 32 ± 5 32 ± 4 0.464
RBCs red blood cells, FFP fresh frozen plasma, HCT hematocrit, ANH acute
normovolemic hemodilution
Table 4 Postoperative outcomes (n = 354)
Outcomes Propensity-matched
ANH Non-ANH p valve
Pulmonary infection
no 329 (93.2%) 313 (88.7%)
yes 24 (6.8%) 40 (11.3%) 0.036
Death
no 350 (99.2%) 351 (99.4%)
yes 3 (0.8%) 2 (0.6%) 1.000#
Prolonged wound healing
no 332 (94.1%) 341 (96.6%)
yes 21 (5.9%) 12 (3.4%) 0.109
Stroke
no 352 (99.7%) 350 (99.2%)
yes 1 (0.3%) 3 (0.8%) 0.624#
AF
no 237 (86.8%) 233 (85.7%)
yes 36 (13.2%) 39 (14.3%) 0.696
Resternotomy for postoperative bleeding
no 349 (98.9%) 350 (99.2%)
yes 4 (1.1%) 3 (0.8%) 1.000#
AKI
no 245 (74.0%) 241 (74.6%)
yes 86 (26.0%) 82 (25.4%) 0.862
Stage1 63 (73.3%) 59 (71.9%)
Stage2 15 (17.4%) 18 (22.0%)
Stage3 8 (9.3%) 5 (6.1%)
Ventilation [mean (SD); hours] 17 ± 21 19 ± 29 0.239
ICU [mean (SD); days] 4.4 ± 2.4 4.2 ± 3.1 0.254
LOS [mean (SD); days] 12 ± 9 12 ± 10 0.708
AF atrial fibrillation, AKI acute kidney injury, ANH acute normovolemic
hemodilution, ICU intensive care unit, LOS length of hospital stay
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evidence is needed to confirm the positive effect of mild
volume ANH on cardiac surgery outcomes, including pul-
monary complication.
Limitations
There were some limitations in this study. Firstly, due to
clear and strict indications, ANH [2] could not be per-
formed widely for all paitents. Secondly, although the strict
exclusion criteria and propensity score adjustment were as-
sumed to minimize biases, the potential bias factors may
not be completely eliminated in a retrospective study.
Thirdly, although no significant difference was observed be-
tween the two matched groups regarding intraoperative
tranexamic acid adminstration, the administration of tran-
examic acid was not absolutely unified in this study. Finally,
population characteristics and the blood saving strategy
were different for each institution; hence, caution should be
used when interpreting our findings.
Conclusions
In conclusion, in our large retrospective study, mild vol-
ume ANH was associated with lower intraoperative RBC
transfusions and postoperative pulmonary infection in
Chinese patients undergoing cardiac surgery. However,
there was no significant difference regarding postoperative
and total perioperative allogeneic transfusions. Further
prospective and randomized studies are needed to confirm
the effects of mild volume ANH on perioperative out-
comes during cardiac surgery.
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